Top Gainers in the Buzz Today

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  04 Mar 2026
 

•   ASNS  
   
  -5.26%
•   BW  
   
  -0.76%
•   CANF  
   
  -1.31%
•   EOLS  
   
  +0.36%
•   JZXN  
   
  +6.71%

$ASNS surged 55.58% after hours to $0.29, fueled by a new contract with the California Department of Transportation. Actelis Networks will deploy its MetaLight solution as part of a $120 million modernization project in San Mateo County. The contract builds on recent government wins in Orange and Ventura counties as well as follow-on orders from Washington D.C., highlighting strong demand for cost-efficient fiber-grade Ethernet over existing copper infrastructure. Volume spiked 186% above average, signaling heavy investor interest in government-backed growth.

$JZXN jumped 87.04% to $1.59 on the announcement of a $1 billion strategic agreement to acquire 10,000 BTC from a prominent global digital asset investor. The move strengthens JZXN position in the cryptocurrency ecosystem, creating long-term strategic partnerships and expanding its digital asset footprint. The outsized volume of 40.68M shares, nearly nine times average daily trading, reflects market enthusiasm for transformative blockchain plays with institutional backing.

$BW gained 45.86% to $11.80 following multiple positive catalysts. The company reported a narrower Q4 loss from continuing operations at $3.5M versus $53.8M last year, with GAAP EPS of -$0.05 beating expectations by $0.02 and revenue of $161M exceeding estimates by $5.4M. Additionally, BW received the full notice to proceed on a $2.4B power generation project, reinforcing its backlog and long-term cash flow potential. Strong institutional interest and a clear path to profitability drove volume nearly seven times its 30-day average.

$EOLS climbed 35.35% to $5.59 after Evolus outlined 2026 revenue guidance of $327M–$337M and emphasized expanding its international footprint and product portfolio. Investors are reacting to both near-term financial visibility and the strategic expansion of its aesthetics and wellness products. Trading volume surged to nearly 10M shares, signaling confidence in Evolus’ growth trajectory and execution capabilities.

$CANF advanced 26.5% to $6.14 after announcing the successful Phase 2a trial of Namodenoson in pretreated pancreatic cancer patients. The drug met its primary endpoint, demonstrating improved overall survival and a favorable safety profile. Separately, the company entered an agreement allowing immediate exercise of warrants at a reduced price, raising approximately $4M in gross proceeds. The combination of clinical success and capital infusion positions CANF for further pipeline development and investor interest in its oncology assets.

View All Headlines